Emcure Pharmaceuticals Limited (EMCURE)

Current Price: ₹0.00

Back to Home
Stock Performance

Quarterly Financials

Consolidated Standalone
Particulars Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 1,815.14 2,001.98 1,962.63 2,116.25 2,100.54 2,269.82 2,363.48 2,469.70
YOY Revenue Growth % - - - - 15.72% 13.38% 20.42% 16.7%
Other Income 23.44 35.65 3.90 4.45 3.70 3.12 1.85 3.99
Total Income 1,838.58 2,037.64 1,966.53 2,120.70 2,104.23 2,272.95 2,365.33 2,473.70
Total Expenses + 1,127.44 1,223.93 1,225.12 1,849.71 1,809.98 1,931.53 2,013.39 2,142.82
Cost of Materials Consumed 331.72 391.49 399.83 403.87 432.50 420.46 421.23 418.58
Employee Benefit Expense 350.40 355.59 366.93 373.37 393.47 384.62 387.33 386.78
Other Expenses 445.32 476.85 458.36 448.37 488.28 520.19 520.98 600.29
Operating Profit 687.70 778.05 737.51 266.54 290.56 338.29 350.09 326.88
OPM % 37.9% 38.9% 37.6% 12.6% 13.8% 14.9% 14.8% 13.2%
Profit Before Tax + 207.41 273.41 229.92 260.61 290.76 341.42 313.79 341.18
Tax Expense 54.82 71.86 73.83 63.38 75.97 90.05 82.42 97.44
Tax % 26.4% 26.3% 32.1% 24.3% 26.1% 26.4% 26.3% 28.6%
Profit After Tax 152.59 201.55 156.09 197.24 214.79 251.37 231.37 243.74
EPS (Basic) 7.95 10.33 8.12 9.97 10.92 12.85 12.16 12.84

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2025
Revenue from Operations 7,896.00
YOY Revenue Growth % -
Other Income 67.26
Total Income 7,963.26
Total Expenses + 6,981.53
Cost of Materials Consumed 1,526.90
Employee Benefit Expense 1,446.29
Other Expenses 1,828.72
Operating Profit 914.47
OPM % 11.6%
Profit Before Exceptional 981.73
Exceptional Items -10.38
Profit Before Tax + 971.35
Tax Expense 263.88
Tax % 27.2%
Profit After Tax 707.47
EPS (Basic) 36.43

Balance Sheet

Particulars Mar 2025
ASSETS
Non-Current Assets + 3,582.82
Property, Plant & Equipment 1,953.60
Capital Work in Progress 124.06
Non-Current Investments 19.34
Goodwill 367.78
Other Intangible Assets 875.36
Current Assets + 4,649.90
Inventories 1,931.81
Trade Receivables 2,002.24
Cash and Cash Equivalents 155.54
Current Investments 76.04
LIABILITIES & EQUITY
Total Equity 0.00
Equity Share Capital 189.48
Other Equity 4,256.70
Non-Current Liabilities 922.90
Current Liabilities 2,668.27
Total Liabilities 3,591.17

Cash Flow Statement

Particulars Mar 2025
Cash from Operating Activities 851.71
Cash from Investing Activities -94.00
Cash from Financing Activities -813.96
Net Increase/Decrease in Cash -58.30